Angiogenesis plays a pivotal role in normal ovarian physiology as well as in the progression
of ovarian cancer through ascites formation and metastatic spread. Bevacizumab (Avastin® …

Angiogenesis is one of the hallmarks of cancer and plays a crucial role in carcinogenesis
and progression of epithelial ovarian cancer. Antiangiogenic agent is the first approved …

Ovarian cancer is clinically characterized by advanced stage at presentation, transient
chemosensitivity, and stagnant long-term survivorship rates despite a broadening portfolio of …

Resistance to chemotherapy is among the most important issues in the management of
ovarian cancer. Unlike cancer cells, which are heterogeneous as a result of remarkable …

Ovarian cancer presents at advanced stage in around 75% of women, and despite
improvements in treatments such as chemotherapy, the 5-year survival from the disease in …

Combination vascular-targeted therapies (VTTs) represent a promising approach for
patients with platinum-resistant recurrent ovarian cancer (OC). VTTs include two …

Although significant improvements in standard therapy for ovarian carcinoma have been
made over the past decade, current treatment is limited by the development of resistance to …

Cancer of the ovarian epithelium is the fourth most common cause of death from cancer in
women and the leading cause of death from gynecologic cancer. At the time of diagnosis …

Background Many women with ovarian cancer eventually develop resistance to
conventional chemotherapy drugs, and so novel agents are being developed to target …

Results of standard chemotherapy in ovarian cancer are hampered by the development of
drug resistance leading to disease recurrence. This prompted interest in the development of …